You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Medtronic
Johnson and Johnson
Merck
AstraZeneca

Last Updated: April 1, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for TAK-901


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug TAK-901?

TAK-901 is an investigational drug.

There have been 323 clinical trials for TAK-901. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2016.

The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).

There are five US patents protecting this investigational drug and eighty-six international patents.

Recent Clinical Trials for TAK-901
TitleSponsorPhase
Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Participants With Persistent/Chronic Primary Immune ThrombocytopeniaMillennium Pharmaceuticals, Inc.Phase 2
Efficiency of Methotrexate and Tofacitinib in Mild and Moderate PatientsShanghai Zhongshan HospitalPhase 4
A Pharmacokinetic and Safety Study of TAK-925 in Participants With Idiopathic HypersomniaMillennium Pharmaceuticals, Inc.Phase 1

See all TAK-901 clinical trials

Clinical Trial Summary for TAK-901

Top disease conditions for TAK-901
Top clinical trial sponsors for TAK-901

See all TAK-901 clinical trials

US Patents for TAK-901

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TAK-901   Start Trial Use of small molecules to enhance MAFA expression in pancreatic endocrine cells Janssen Biotech, Inc. (Horsham, PA)   Start Trial
TAK-901   Start Trial Kinase inhibitors Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
TAK-901   Start Trial Kinase inhibitors Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
TAK-901   Start Trial Kinase inhibitors Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
TAK-901   Start Trial Combination therapy using bispecific anti-c-Met/anti-EGFR antibody and c-Src inhibitor SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for TAK-901

Drugname Country Document Number Estimated Expiration Related US Patent
TAK-901 Argentina 100446 2034-05-16   Start Trial
TAK-901 Australia 2015259573 2034-05-16   Start Trial
TAK-901 Canada 2949056 2034-05-16   Start Trial
TAK-901 China 106414720 2034-05-16   Start Trial
TAK-901 European Patent Office 3143127 2034-05-16   Start Trial
TAK-901 Japan 2017515507 2034-05-16   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
AstraZeneca
McKinsey
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.